Literature DB >> 10350333

Interleukin-10 and Gp130 cytokines in human multiple myeloma.

B Klein1, Z Y Lu, Z J Gu, V Costes, M Jourdan, J F Rossi.   

Abstract

Interleukin (IL)-10 is a critical cytokine involved in the terminal differentiation of B cells into plasma cells. IL-10 is also involved in multiple myeloma, a malignant plasma cell disorder. IL-6 and, more generally the cytokines activating the gp130 IL-6 transducer, are major survival and proliferation factors of myeloma cells. IL-10 is also a growth factor of malignant plasma cells, produced by myeloma cells from about half the patients and is detected in the plasma of patients with plasma cell leukemia or solitary plasmacytoma. The myeloma cell growth activity of IL-10 is mediated through a gp130 cytokine, oncostatin M (OSM), that is frequently produced by myeloma cells. Myeloma cells fail to express OSM receptors but IL-10, by inducing it, confers on them the sensitivity to OSM.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10350333     DOI: 10.3109/10428199909083381

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

Review 1.  Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease.

Authors:  Sara De Iudicibus; Raffaella Franca; Stefano Martelossi; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

Review 2.  Immunotherapeutic approaches to treat multiple myeloma.

Authors:  Mieke W H Roeven; Willemijn Hobo; Nicolaas Schaap; Harry Dolstra
Journal:  Hum Vaccin Immunother       Date:  2013-12-11       Impact factor: 3.452

Review 3.  Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.

Authors:  Akshata Udyavar; Terrence L Geiger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-08-01       Impact factor: 4.291

4.  TPL2 kinase regulates the inflammatory milieu of the myeloma niche.

Authors:  Chelsea Hope; Samuel J Ollar; Erika Heninger; Ellen Hebron; Jeffrey L Jensen; Jaehyup Kim; Ioanna Maroulakou; Shigeki Miyamoto; Catherine Leith; David T Yang; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Fotis Asimakopoulos
Journal:  Blood       Date:  2014-04-10       Impact factor: 22.113

5.  Loss of tissue expression of interleukin-10 promotes the disease progression of colorectal carcinoma.

Authors:  Yuji Toiyama; Chikao Miki; Yasuhiro Inoue; Sayaka Minobe; Hiroko Urano; Masato Kusunoki
Journal:  Surg Today       Date:  2009-12-29       Impact factor: 2.549

6.  Cucurbitacin B exerts anti-cancer activities in human multiple myeloma cells in vitro and in vivo by modulating multiple cellular pathways.

Authors:  Tai Yang; Jin Liu; Mali Yang; Ning Huang; Yueling Zhong; Ting Zeng; Rong Wei; Zhongjun Wu; Cui Xiao; Xiaohua Cao; Minhui Li; Limei Li; Bin Han; Xiaoping Yu; Hua Li; Qiang Zou
Journal:  Oncotarget       Date:  2017-01-24

7.  Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.

Authors:  Barbara Zdzisińska; Agnieszka Bojarska-Junak; Anna Dmoszyńska; Martyna Kandefer-Szerszeń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

8.  Cytokine gene polymorphisms support diagnostic monitoring of Romanian multiple myeloma patients.

Authors:  C Banu; A Moise; C V Arion; D Coriu; A Tănase; I Constantinescu
Journal:  J Med Life       Date:  2011-08-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.